Although NSAIDs and physical therapy remain the first-line treatment recommendations for SpA, therapy options are evolving rapidly with advances in understanding, classifying and diagnosing the disease. TNF blockers are effective in NSAID-resistant disease but other biologic agents have thus far failed to deliver results. New capacities to enroll patients at an earlier stage in the disease, and to stratify studies by SpA subtype, will facilitate further therapeutic developments.
